Novo Nordisk Net Long-Term Debt 2010-2025 | NVO
Novo Nordisk net long-term debt from 2010 to 2025. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
Novo Nordisk Annual Net Long-Term Debt
(Millions of US $) |
| 2024 |
$10,593 |
| 2023 |
$-213 |
| 2022 |
$-341 |
| 2021 |
$2,461 |
| 2020 |
$725 |
| 2019 |
$-111 |
| 2018 |
$14 |
| 2017 |
$N/A |
| 2016 |
$N/A |
| 2015 |
$N/A |
| 2014 |
$N/A |
| 2013 |
$N/A |
| 2012 |
$-87 |
| 2011 |
$N/A |
| 2010 |
$N/A |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.000B |
$42.122B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
